Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study

Fig. 2

a Overview of baseline characteristics, tumor response, and pathological response in 30 patients. Each column represents one patient, with patient IDs listed at the bottom; each row represents a different feature. The definition of different colors is presented in the “Color Legend” on the right. b The relationship between PD-L1 CPS and pathological response. c The correlation between TTS and pathological response. PD-L1, programmed death ligand 1; CPS combined positive score, TTS time to surgery, SCC squamous-cell carcinoma, OPR optimal pathological response, RT radiotherapy, LVSI lymphatic vascular space invasion, MPR major pathological response, FIGO International Federation of Gynecology and Obstetrics, AC adenocarcinoma, CR complete response, PR partial response. SD stable disease, NA not applicable, HPV human papillomavirus, CCRT concurrent chemoradiotherapy, CPS combined positive score, pCR pathological complete response

Back to article page